Personalized medication for overactive bladder with imidafenacin treatment

Personalized medication for overactive bladder with imidafenacin treatment - PERMIT study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000025820

Enrollment

100

Registered

2017-03-15

Start date

2017-03-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overactive bladder

Interventions

[Personalized medication] First 2 weeks: imidafenacin 0.1mg x 2/day (Fixed) Following 3-12 weeks: imidafenacin 0.1-0.4mg/day depending on the subjective decision of the patients [Controlled medicati

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: OABSS: urgency score 3 and more, and total score 6 and more

Exclusion criteria

Exclusion criteria: - Urinary retention within the last 12 months - Post-void residual urine 100mL and more - Indwelling catheter or Intermittent catheterization - Sleep apnea syndrome, Restless legs syndrome or insomnia - acute urinary infection

Design outcomes

Primary

Measure	Time frame
King's Health Questionnaire	—

Secondary

Measure	Time frame
Overactive bladder symptom score (OABSS) IPSS-QOL score adverse events	—

Countries

Japan

Contacts

Public ContactKazumasa Torimoto

Nara Medical University Urology

torimoto@naramed-u.ac.jp0744-22-3051

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026